RePORT India Partners: 

  • Department of Pulmonary Immunology, Center for Biomedical Research, University of Texas Health Science Center at Tyler, USA


Tripathi D, Venkatasubramanian S, Cheekatla SS, et al. A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic mice. Nature Communications. 2016;7:13896. doi:10.1038/ncomms13896.


Pancreatic islet transplantation is a promising potential cure for type 1 diabetes (T1D). Islet allografts can survive long term in the liver parenchyma. Here we show that liver NK1.1+ cells induce allograft tolerance in a T1D mouse model. The tolerogenic effects of NK1.1+ cells are mediated through IL-22 production, which enhances allograft survival and increases insulin secretion. Increased expression of NKG2A by liver NK1.1+ cells in islet allograft-transplanted mice is involved in the production of IL-22 and in the reduced inflammatory response to allografts. Vaccination of T1D mice with a CpG oligonucleotide TLR9 agonist (ODN 1585) enhances expansion of IL-22-producing CD3-NK1.1+ cells in the liver and prolongs allograft survival. Our study identifies a role for liver NK1.1+ cells, IL-22 and CpG oligonucleotides in the induction of tolerance to islet allografts in the liver parenchyma.

Access full text


Tripathi D, Venkatasubramaniam S, Cheekatla SS, Paidipally P, Welch E, Tvinnereim A, Vankayalapati R
Resource Type:
Media Type: